- Conditions
- ESRD
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–35
of 35
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
- Interventions
- Suboxone, Truvada, Mavyret
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Greensboro, North Carolina
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
- Conditions
- Hepatitis C, Chronic, Nonadherence, Patient
- Interventions
- Digital Medicine
- Device
- Lead sponsor
- Proteus Digital Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more
- Conditions
- Hepatitis C, HCV
- Interventions
- Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
- Conditions
- Hepatitis C
- Interventions
- Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
- Diagnostic Test · Other · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Long Island City, New York • New York, New York
- Conditions
- End Stage Renal Disease
- Interventions
- Zepatier, Mavyret
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- End Stage Renal Disease, Chronic Hepatitis c
- Interventions
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 34 Years to 44 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Renal Disease, Hepatitis C
- Interventions
- 300mg glecaprevir/pibrentasivir 120mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Kidney Transplant, Hepatitis C, HCV
- Interventions
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio